FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2901014718> ?p ?o ?g. }

• W2901014718 endingPage "36249" @default.
• W2901014718 startingPage "36238" @default.
• W2901014718 abstract "// Elodie Long-Mira 1, 2, 3, * , Marius Ilie 1, 2, 3, * , Emmanuel Chamorey 4 , Florence Leduff-Blanc 5 , Henri Montaudié 5 , Virginie Tanga 3 , Maryline Allégra 3 , Virginie Lespinet-Fabre 3 , Olivier Bordone 3 , Christelle Bonnetaud 3 , Renaud Schiappa 4 , Catherine Butori 1 , Coraline Bence 1 , Jean-Philippe Lacour 5 , Véronique Hofman 1, 2, 3 and Paul Hofman 1, 2, 3 1 Université Côte d’Azur, CHU Nice, FHU OncoAge, Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Nice, France 2 Université Côte d’Azur, CNRS, INSERM, IRCAN, FHU OncoAge, Team 4, Nice, France 3 Université Côte d’Azur, CHU Nice, FHU OncoAge, Hospital-Integrated Biobank, Nice, France 4 Antoine Lacassagne Comprehensive Cancer Center, FHU OncoAge, Biostatistics Unit, Nice, France 5 Université Côte d’Azur, CHU Nice, Department of Dermatology, Archet Hospital, Nice, France * These authors contributed equally to this work Correspondence to: Marius Ilie, email: ilie.m@chu-nice.fr Keywords: metastatic melanoma; BRAF; NRAS; cfDNA; IDYLLA™ Received: July 19, 2018      Accepted: November 01, 2018      Published: November 16, 2018 ABSTRACT The mutation status of the BRAF and NRAS genes in tumor tissue is used to select patients with metastatic melanoma for targeted therapy. Cell-free circulating DNA (cfDNA) represents an accessible, non-invasive surrogate sample that could provide a snapshot of the BRAF and NRAS genotype in these patients. We investigated the feasibility of the Idylla™ assay for detection of BRAF and NRAS mutations in cfDNA of 19 patients with metastatic melanoma at baseline and during the course of treatment. The cfDNA genotype obtained with Idylla was compared to the results obtained with matched-tumor tissue and to clinical outcome. At baseline, 47% of patients harbored a BRAFV600 mutation in their cfDNA. Two months after targeted treatment the BRAFV600 mutant cfDNA was undetectable in all patients and 3 were disease-free. Moreover, 15% of patients harbored a NRAS mutation that was detected with plasma before treatment. The sensitivity and specificity were 80% and 89% for the BRAF status, and 79% and 100% for the NRAS status in pretreatment cfDNA compared to results obtained with a tissue test. Due to the small size of the population, no significant correlation was observed between the presence of BRAF or NRAS mutations in cfDNA and the metastatic tumor load or overall survival. In conclusion, this study demonstrated that evaluation with the Idylla system of the BRAF and NRAS mutation status in cfDNA may be a surrogate for determination of the BRAF and NRAS status in tumor tissue." @default.
• W2901014718 created "2018-11-29" @default.
• W2901014718 creator A5000808569 @default.
• W2901014718 creator A5007402718 @default.
• W2901014718 creator A5023675047 @default.
• W2901014718 creator A5026405907 @default.
• W2901014718 creator A5028693753 @default.
• W2901014718 creator A5029463040 @default.
• W2901014718 creator A5035956513 @default.
• W2901014718 creator A5038569833 @default.
• W2901014718 creator A5049562438 @default.
• W2901014718 creator A5055432088 @default.
• W2901014718 creator A5058938160 @default.
• W2901014718 creator A5066227680 @default.
• W2901014718 creator A5076383410 @default.
• W2901014718 creator A5076511635 @default.
• W2901014718 creator A5080197227 @default.
• W2901014718 date "2018-11-16" @default.
• W2901014718 modified "2023-10-18" @default.
• W2901014718 title "Monitoring BRAF and NRAS mutations with cell-free circulating tumor DNA from metastatic melanoma patients" @default.
• W2901014718 cites W1215089631 @default.
• W2901014718 cites W1545514894 @default.
• W2901014718 cites W1575391989 @default.
• W2901014718 cites W1919269372 @default.
• W2901014718 cites W1963853602 @default.
• W2901014718 cites W1966256831 @default.
• W2901014718 cites W1967347815 @default.
• W2901014718 cites W1989773675 @default.
• W2901014718 cites W2044771773 @default.
• W2901014718 cites W2056199226 @default.
• W2901014718 cites W2062088207 @default.
• W2901014718 cites W2086751758 @default.
• W2901014718 cites W2096837288 @default.
• W2901014718 cites W2104641188 @default.
• W2901014718 cites W2105660237 @default.
• W2901014718 cites W2113716683 @default.
• W2901014718 cites W2121545342 @default.
• W2901014718 cites W2128327828 @default.
• W2901014718 cites W2131256900 @default.
• W2901014718 cites W2134232003 @default.
• W2901014718 cites W2140575188 @default.
• W2901014718 cites W2152897456 @default.
• W2901014718 cites W2164667198 @default.
• W2901014718 cites W2167059308 @default.
• W2901014718 cites W2167806838 @default.
• W2901014718 cites W2169198176 @default.
• W2901014718 cites W2171237493 @default.
• W2901014718 cites W2179502834 @default.
• W2901014718 cites W2190346722 @default.
• W2901014718 cites W2206684187 @default.
• W2901014718 cites W2220812108 @default.
• W2901014718 cites W2258535515 @default.
• W2901014718 cites W2271392525 @default.
• W2901014718 cites W2290892914 @default.
• W2901014718 cites W2294395959 @default.
• W2901014718 cites W2332945220 @default.
• W2901014718 cites W2401050525 @default.
• W2901014718 cites W2401650605 @default.
• W2901014718 cites W2465860350 @default.
• W2901014718 cites W2554948810 @default.
• W2901014718 cites W2560367415 @default.
• W2901014718 cites W2605806843 @default.
• W2901014718 cites W2611081422 @default.
• W2901014718 cites W2727584377 @default.
• W2901014718 cites W2744838869 @default.
• W2901014718 cites W2769575972 @default.
• W2901014718 cites W2801901721 @default.
• W2901014718 cites W2805768122 @default.
• W2901014718 cites W4235642752 @default.
• W2901014718 cites W745076224 @default.
• W2901014718 doi "https://doi.org/10.18632/oncotarget.26343" @default.
• W2901014718 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6281416" @default.
• W2901014718 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30546839" @default.
• W2901014718 hasPublicationYear "2018" @default.
• W2901014718 type Work @default.
• W2901014718 sameAs 2901014718 @default.
• W2901014718 citedByCount "26" @default.
• W2901014718 countsByYear W29010147182019 @default.
• W2901014718 countsByYear W29010147182020 @default.
• W2901014718 countsByYear W29010147182021 @default.
• W2901014718 countsByYear W29010147182022 @default.
• W2901014718 countsByYear W29010147182023 @default.
• W2901014718 crossrefType "journal-article" @default.
• W2901014718 hasAuthorship W2901014718A5000808569 @default.
• W2901014718 hasAuthorship W2901014718A5007402718 @default.
• W2901014718 hasAuthorship W2901014718A5023675047 @default.
• W2901014718 hasAuthorship W2901014718A5026405907 @default.
• W2901014718 hasAuthorship W2901014718A5028693753 @default.
• W2901014718 hasAuthorship W2901014718A5029463040 @default.
• W2901014718 hasAuthorship W2901014718A5035956513 @default.
• W2901014718 hasAuthorship W2901014718A5038569833 @default.
• W2901014718 hasAuthorship W2901014718A5049562438 @default.
• W2901014718 hasAuthorship W2901014718A5055432088 @default.
• W2901014718 hasAuthorship W2901014718A5058938160 @default.
• W2901014718 hasAuthorship W2901014718A5066227680 @default.
• W2901014718 hasAuthorship W2901014718A5076383410 @default.
• W2901014718 hasAuthorship W2901014718A5076511635 @default.
• W2901014718 hasAuthorship W2901014718A5080197227 @default.

• next